heart failure heart failure
Conditions
Interventions
Random Allocation of teprenone (GGA) to the patients recieved standard therapeutic
strategies for heart failure.
Sponsors
Akasaka Takeshi
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. inpatient 2. patients recerving standard treatment for heart failure in cardiology 3. patients aged 18 years or older at the time of concent(regardless of gender) 4. patients who have received sufficient explanation of this study and have voluntarily consented by the mselves or their substitute.
Exclusion criteria
Exclusion criteria: 1.patients taking GGA (including over-the-counter drugs contains GGA,such as Selbelle etc) within 1 month before obtaining consent 2.patients with severe valvular disease, acute myocardial infarction, unstable angina 3.patients receiving WAON therapy(soothing warm therapy) within 1 month before obtaining consent 4.patients who is not able to take capsels 5.patients with serious liver disease distinct from congestion 6.patients receiving dialysis 7.pregnant or potentially pregnant women 8.lactating women 9.patients with allergies to GGA 10.patients without the agreement to participate in this study by them or their substitute 11.patients who evaluated by the principal investigator to be inappropriate as a research subject
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in NT-ProBNP value 24 weeks after the start of GGA administration. Changes in CK-MB and troponin values as indicators of cell injury. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1.change in BNP value at the time of 1,2,4,12,24 weeks after the start of GGA administration. 2.following items at the time of 1,2,4,12,24 weeks after the start of GGA administration. -subjective symptoms (NYHA classification) -KCCQ (Kansas City Cardiomyopathy Questionnaire) -left ventricular ejection fraction, diastolic function (E/A, DecT, E/e), pulmonary artery pressure evaluated by echocardiogram -CTR, tracheal bifurcation angle evaluated by chest X-ray -Physical function: Grip power, 6-minute walking distance, walking speed, comprehensive lower limb function -5-year survival prediction using cardiac sympathetic nerve function (MIBG)) -heart failure readmission, all cause death, cardiac death | — |
Contacts
Public ContactEtusko Shimizu
Clinical Research Center
Outcome results
None listed